DBTX(Delisted)
Decibel Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DBTX
Decibel Therapeutics, Inc.
A clinical-stage biotech company that develops transformative treatments for hearing and balance disorders
1325 Boylston Street, Suite 500, Boston, Massachusetts 02215
--
Decibel Therapeutics, Inc., was incorporated under the laws of the State of Delaware on November 26, 2013 as Hearing, Inc. Their name was changed to Decibel Therapeutics, Inc., on April 24, 2014. They are a clinical-stage biotechnology company dedicated to the discovery and development of translational therapies for hearing and balance disorders, one of the largest areas of unmet need in medicine. They aim to restore and improve hearing and balance through the recovery and regeneration of functional hair cells and non-sensory support cells in the inner ear.
Company Financials
EPS
DBTX has released its 2023 Q2 earnings. EPS was reported at -0.73, versus the expected -0.57, missing expectations. The chart below visualizes how DBTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
